Ce site a été mis à jour le 14 mars 2017

Menopause Imprimer
Ensrud et al (Circulation. 2010 Oct 11. [Epub ahead of print]) provided the 5-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial. 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD events 32% (HR, 0.68; 95%CI, 0.50- 0.93), including the risk of coronary revascularization (HR, 0.56, 95% CI, 0.32 - 0.98). Reductions in risk of hospitalization for unstable angina (HR, 0.55; 95% CI, 0.29- 1.04) and diagnosis of new ischemic heart disease (HR, 0.52; 95% CI, 0.26 -1.04) nearly reached significance (P=0.06 for both comparisons). Although both hazard ratios were <1.0, no significant effect of lasofoxifene at 0.5 mg/d was demonstrated for coronary death or nonfatal myocardial infarction. The reduction in CHD events with lasofoxifene 0.25 mg/d was not significant. The effectiveness of lasofoxifene 0.5 mg/d in reducing CHD events was similar across strata of major cardiovascular risk factors.
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн